Back to journals
Academic Journal

Lancet Psychiatry

7 Papers Indexed in Blossom

Data updated

Research Footprint

Lancet Psychiatry has 7 tracked papers indexed in Blossom (2016–2026) from 58 authors, most often covering MDMA, Ketamine and Psilocybin, across Depressive Disorders, Substance Use Disorders (SUD) and Safety & Risk Management.

Published Papers

Paywallmeta

Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatry

This review (2026) discusses how placebo effects are measured and interpreted in randomised controlled trials in psychiatry, with a focus on blinding and expectancy in psychedelic trials, large placebo responses in device or procedure-based studies, and shared brain mechanisms between placebo effects and psychiatric treatments.

Published
Journal
Lancet Psychiatry
Authors
Taylor, J. J., Szigeti, B., Silverberg, N. D., Ahmadzad-Asl, M., Kare, M., Webler, R., Orsini, D. K., Rosenblat, J. D., Bschor, T., Baethge, C., Sinyor, M., Nicholson, T. R., Wager, T. D., Burke, M. J.
Paywallindividual

Treatment with psychedelics is psychotherapy: beyond reductionism

This opinion piece (2023) challenges the traditional conceptualization of psychedelic-assisted psychotherapy (PAP/PAT), emphasizing that the therapeutic effects of psychedelics should not be solely attributed to the substance itself but also to the importance of psychotherapy. The authors argue against reducing the role of psychotherapy to mere psychological support for safety, advocating for a more integrated approach to understanding and studying the therapeutic potential of psychedelics in treating psychiatric disorders.

Published
Journal
Lancet Psychiatry
Authors
Gründer, G., Brand, M., Mertens, L. J., Scharf, D. J., Spangemacher, M., Jungaberle, H., Wolff, M., Kartner, L.
Paywallmeta

Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability

This review (2022) uses data from three randomised-controlled trials (RCTs), eight open-label trials and 30 case series to explore the efficacy, safety and tolerability of using ketamine in the treatment of depression. Ketamine was found to have sustained antidepressant effects when administered intravenously, intranasally, orally and possibly intramuscularly and was found to be well-tolerated.

Published
Journal
Lancet Psychiatry
Authors
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Spijker, J., Kamphuis, J., Schoevers, R. A.
Open Accessindividual

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial

This Phase II clinical trial (n=26) finds that MDMA-assisted psychotherapy (75-125 mg) led to significant and sustained decreases in PTSD (CAPS-IV) scores as compared to an active placebo (30 mg). At the 12-month follow-up, the average CAPS-IV score had dropped from 87 to 39 (67% no longer qualified for PTSD diagnosis).

Published
Journal
Lancet Psychiatry
Authors
Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A., Jerome, L., Wagner, M. T., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Doblin, R.
Open Accessmeta

Side-effects associated with ketamine use in depression: a systematic review

This systematic review (2017) examined the reported side-effects of ketamine treatment for depression across 288 published reports and identified that headache, dizziness, dissociation, elevated blood pressure, and blurred vision were the most common in response to intravenous infusion. The most common acute psychiatric side-effect was anxiety, but there was no conclusive evidence about long-term side effects from the currently available studies.

Published
Journal
Lancet Psychiatry
Authors
Short, B., Fong, J., Galvez, V., Shelker, W., Loo, C. K.
Open Accessindividual

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

This is the first modern study (n=12) on psilocybin and its effects on treatment-resistant depression (TRD). It shows that two sessions with psilocybin (10mg and 25mg) in combination with psychological support can reduce depressive symptoms over periods of one week to three months after treatment. Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred.

Published
Journal
Lancet Psychiatry
Authors
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Nutt, D. J., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, H. V.

Quick Facts

Papers Indexed
7
Publisher
Elsevier
Website
Visit